• United Therapeutics submitted an FDA New Drug Application in June 2026 for ralinepag to treat pulmonary arterial hypertension.
• An FDA supplemental New Drug Application was also filed for nebulized treprostinil to treat idiopathic pulmonary fibrosis.
• Ralinepag remains investigational. Nebulized treprostinil remains investigational for idiopathic pulmonary fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260828683707) on August 28, 2026, and is solely responsible for the information contained therein.